Contineum Therapeutics (Contineum Therapeutics) ROCE % : -24.73% (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Contineum Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -24.73%.

Contineum Therapeutics ROCE % Historical Data

The historical data trend for Contineum Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics ROCE % Chart

Contineum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-42.89

-43.42

27.83

Contineum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
ROCE %	-	-	-68.80	-	-24.73

Contineum Therapeutics ROCE % Calculation

Contineum Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	23.378	/	( ( (50.636 - 7.55)	+	(130.386 - 5.484) )	/ 2 )
	=	23.378	/	( (43.086	+	124.902)	/ 2 )
	=	23.378	/	83.994
	=	27.83 %

Contineum Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-31.72	/	( ( (139.045 - 7.436)	+	(130.386 - 5.484) )	/ 2 )
	=	-31.72	/	( ( 131.609	+	124.902 )	/ 2 )
	=	-31.72	/	128.2555
	=	-24.73 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Contineum Therapeutics (NAS:CTNM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Contineum Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics (Contineum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.contineum-tx.com

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus

Contineum Therapeutics Announces Pricing of Initial Public Offering

By GlobeNewswire • 04-05-2024